NOISEReport
Coverage history

Assembled by NOISE.

Report / Tech

Published by NOISE

Leukemia vaccine succeeds in Phase 3 trial, adding to cancer advances

From Evening NOISE.

Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday that their vaccine for acute myeloid leukemia succeeded in a Phase 3 trial of 126 patients. Sellas said the vaccine cut the risk of death by 41 percent compared with other treatments, with median survival of 24 months versus 14.7 months; the trial involved patients in a second or later remission who could not receive a bone-marrow transplant. The result adds to a year of positive cancer-vaccine trial news, but full data are still pending, and Sellas plans to prepare an FDA approval submission in the first half of 2027.

Saved versions

These dates record changes to NOISE’s copy. They are not event dates.

  1. Saved copyCurrentIn saved edition